Contact us on (+33) 0174 311 131 or contact@bionext.com. Bionext - go to homepage Home Products Communications News Our team Contact Latest news Read more BioSight targets it rightly - Structural homology and beyond in E. Coli DHODH on August 23, 2017 SUMMARY BioSight* is a BIONEXT’s web platform dedicated to the retrieval and assessment of local surface similarities. Here, BioSight was challenged on a structure of the protein E. coli dihydroorotate dehydrogenase (E. coli DHODH) complexed with orotate. Among the first hits retrieved were legitimate DHODH homologs and also the similarly folded dihydropyrimidine dehydrogenase. Surprisingly, the molybdenum storage protein was also significantly highly ranked by BioSight despite its structural differences with the DHODH query. Read more Bionext wants to raise 5 million for the commercialization of its new service on August 21, 2017 Press Release from Le Journal des Entreprises Bionext, a French biotechnology company located in Strasbourg, has just launched a Web platform dedicated to pharmaceutical research and now ambitions to raise five million for its commercialization. See more: Source Read more BiovizJS: a versatile 3D molecular visualizer anywhere, anytime and with any device on August 14, 2017 SUMMARY Structural properties and physicochemical interactions are of critical interest when studying biomolecules. Therefore, BIONEXT has developed BiovizJS, a 3D molecular visualization Web application runnable on any network connected device. This tool provides both improved and exclusive features for molecular visualization with the aim to enhance your experience in many situations and from any devices. In order to ease its integration into your website, it provides a straightforward API. Read more Fit for fitting: BIONEXT-DSS, a dataset of similar sites on July 25, 2017 SUMMARY Predicting novel binding pockets for a given medicine is a challenging task with numerous pharmaceutical applications. Based on the principle that “similar binding sites share similar ligands”1, many binding pocket prediction algorithms are based on the evaluation and retrieval of pockets being similar to a known binding site. Two distinct yet connected problematics can hence be described: (i) the ability to retrieve known sites for a given ligand in distinct proteins, and (ii) the retrieval of similar sites. Learn about BioSight, our main product BioSight Target Analysis is dedicated to the retrieval of common patterns at the surface of macromolecules. Based on a user defined query pattern, Target Analysis iterates over a large database of structures and identifies at the surface of these macromolecules areas that are similar to the query. Learn more Go to BioSight Do you want to see more? Go to Products Our Financers About us BIONEXT is a French biotechnology company dedicated to the better understanding and treatment of various diseases. BIONEXT aims to accelerate and improve the effectiveness of drug development and biological research by developping programs and software-based tools to tackle problematics of prime importance in the pharmaceutical field, such as drug profile assesment or suggestion of drug repurposing. Latest news BioSight targets it rightly - Structural homology and beyond in E. Coli DHODH Bionext wants to raise 5 million for the commercialization of its new service BiovizJS: a versatile 3D molecular visualizer anywhere, anytime and with any device Contact Headquarter Business Office 8 rue Schertz 88 ter avenue du Général Leclerc 67100 Strasbourg 92100 Boulogne-Billancourt France France Go to contact page Copyright (c) 2009 - 2017, BIONEXT SA, all rights reserved. Template by Bootstrapious. Ported to Hugo by DevCows